[Is there a need for direct renin inhibitors?]

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertension significantly contributes to cardiovascular morbidity and mortality.
• Effective blood pressure control remains a challenge, with over 50% of patients inadequately managed.
• Noncompliance, due to side effects and administration inconvenience, is a primary barrier to BP control.

Discussion:

• Aliskiren, a direct renin inhibitor, demonstrates potent blood pressure-lowering efficacy.
• Its once-daily oral administration and favorable side effect profile (comparable to placebo) enhance patient compliance.
• Aliskiren effectively complements existing antihypertensives like diuretics, ACE inhibitors, and calcium channel blockers.

Key Insights:

• Direct renin inhibition by Aliskiren targets the renin-angiotensin system at its initiation, suppressing renin levels.
• This mechanism contrasts with ACE inhibitors and ARBs, which act downstream and elevate renin.
• Aliskiren's efficacy and tolerability present a promising therapeutic option for hypertension.

Outlook:

• Further prospective studies are warranted to evaluate Aliskiren's impact on morbidity and mortality endpoints.
• Establishing Aliskiren as a first-choice agent requires comprehensive clinical outcome data.
• The drug's role in long-term cardiovascular risk reduction needs to be definitively established.